The Breast Cancer Index (BCI) was previously shown to identify ~20% of postmenopausal patients with early stage, hormone receptor positive (HR+), node negative (N0) breast cancer with minimal (<5%) risk of 10-year distant recurrence (DR) even without receiving adjuvant endocrine therapy (ET). This evidence concerns the gene NR4A1 and breast carcinoma.